Jasper Therapeutics, Inc. (JSPRW)

The immediate outlook is severely bearish due to a catastrophic collapse in liquidity and capital structure. The stock has effectively vanished from the market, trading at $0.012 while the fifty-two-week high was $0.0121 and the low was $0.009, indicating a compressed, illiquid range where price discovery has failed. The company is hemorrhaging cash with free cash flow of -$42 million and operating cash flow of -$68 million, while holding negligible cash reserves of only $14 million against minimal debt, creating an imminent solvency crisis. Fundamentally, the business is a value trap with negative returns on assets and equity, no analyst coverage, and no revenue growth trajectory to support a turnaround. There is no dividend to provide income, and the lack of price history combined with these dire fundamentals makes a long-term hold impossible. The statistical models offer no guidance due to insufficient data, confirming that this is a speculative dead zone rather than a trading opportunity.